Weiss Ratings Reaffirms Sell (E+) Rating for 111 (NASDAQ:YI)

111 (NASDAQ:YI)‘s stock had its “sell (e+)” rating reaffirmed by research analysts at Weiss Ratings in a report released on Tuesday,Weiss Ratings reports.

111 Stock Performance

Shares of 111 stock opened at $6.93 on Tuesday. 111 has a 1 year low of $4.14 and a 1 year high of $12.00. The company has a market capitalization of $59.88 million, a P/E ratio of -10.83 and a beta of 0.44. The company’s fifty day moving average is $7.70 and its two-hundred day moving average is $7.62.

111 (NASDAQ:YI) last released its earnings results on Thursday, June 19th. The company reported ($0.20) EPS for the quarter. The firm had revenue of $486.35 million for the quarter.

Institutional Trading of 111

Hedge funds have recently made changes to their positions in the company. JPMorgan Chase & Co. lifted its stake in shares of 111 by 43,619.9% in the fourth quarter. JPMorgan Chase & Co. now owns 306,039 shares of the company’s stock valued at $191,000 after purchasing an additional 305,339 shares during the period. FIL Ltd acquired a new stake in shares of 111 in the fourth quarter valued at about $450,000. Deuterium Capital Management LLC acquired a new stake in shares of 111 in the first quarter valued at about $81,000. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of 111 in the first quarter valued at about $92,000. Institutional investors and hedge funds own 21.32% of the company’s stock.

About 111

111, Inc engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies.